| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $39.8M | +4.5% | +92.9% |
| SG&A Expense | $6.4M | +19.6% | +163.4% |
| Operating Income | -$46.2M | -6.4% | -1807.3% |
| Net Income | -$42.1M | -8.5% | -8539.0% |
| EPS (Basic) | -$526.11 | — | -870.1% |
| EPS (Diluted) | -$526.11 | — | -870.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $52.7M | -87.6% | — |
| Short-term Investments | $199.6M | +285.6% | — |
| Accounts Receivable | $146K | -62.2% | — |
| Current Assets | $266.5M | -38.4% | — |
| Total Assets | $417.6M | -6.9% | +113.4% |
| Current Liabilities | $43.3M | +23.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$35.9M | — | -4789.0% |
| Capital Expenditures | $24K | — | -85.2% |
| Investing Cash Flow | -$285.4M | — | -1957.2% |
| Financing Cash Flow | $295K | — | +173.0% |
| Free Cash Flow | -$35.9M | — | -3908.4% |
| +2212.4% |
| Total Liabilities | $45.4M | +21.7% | +513.8% |
| Stockholders' Equity | $372.3M | -9.4% | +6152.0% |